Rampart Skin Graft: Clinical Guide for Wound Care Clinicians

Rampart Skin Graft is an amniotic membrane allograft that has emerged as a significant option in the advanced wound care arsenal. For clinicians managing chronic wounds, diabetic foot ulcers, and complex surgical sites, understanding when to select Rampart, how to apply it correctly, and what outcomes to expect is essential for optimizing patient care and navigating reimbursement.

This guide synthesizes the clinical evidence, application techniques, and practical considerations for using Rampart Skin Graft in contemporary wound care practice. For broader context on how amniotic products compare to synthetic alternatives, see our amniotic membrane vs synthetic graft comparison.

What Rampart Skin Graft Is and How It Works

Rampart Skin Graft is a dehydrated human amniotic membrane allograft processed to retain the biological activity of the native tissue while providing a stable, shelf-stable graft for clinical use. The product is derived from donated placental tissue and processed under strict FDA-regulated guidelines to ensure safety, consistency, and efficacy.

The mechanism of action is multifaceted. Amniotic membrane contains a rich extracellular matrix with collagen types I, III, IV, V, and VII, along with fibronectin, laminin, and proteoglycans. More importantly, it retains physiologically relevant concentrations of growth factors including vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-beta).

These growth factors modulate the wound microenvironment in three critical ways. First, they stimulate angiogenesis, bringing oxygen and nutrients to hypoxic wound beds. Second, they recruit fibroblasts and keratinocytes, accelerating the proliferative phase of healing. Third, they modulate inflammation through anti-inflammatory cytokines like interleukin-1 receptor antagonist (IL-1ra) and tissue inhibitors of metalloproteinases (TIMPs), breaking the chronic inflammation cycle that stalls so many wounds.

Indications and Appropriate Patient Selection

Rampart Skin Graft is indicated for wounds that have stalled despite optimal standard care. The typical patient profile includes:

• Diabetic foot ulcers (DFUs) that have not achieved 50% area reduction after 4 weeks of standard care, including offloading, debridement, and moist wound healing.
• Venous leg ulcers (VLUs) with persistent fibrinous wound beds, excessive exudate, or failure to progress toward epithelialization despite compression therapy.
• Surgical wounds with compromised healing due to radiation, poor vascularity, or patient comorbidities such as immunosuppression or malnutrition.
• Partial-thickness burns where accelerated re-epithelialization reduces infection risk and improves cosmetic outcomes.
• Traumatic wounds with significant tissue loss where granulation tissue formation is delayed.

Patient selection also requires attention to contraindications and cautions. Active infection should be controlled before application, though Rampart does carry antimicrobial peptides that may help reduce bioburden. Severe peripheral arterial disease with inadequate perfusion (ABI less than 0.5 or TBI less than 0.3) will compromise graft viability regardless of biological activity. Patients with known hypersensitivity to human-derived tissue products should not receive amniotic allografts.

Application Technique: Step by Step

Proper application is critical to outcomes. The graft must contact viable wound bed tissue to exert its biological effects. Application over necrotic tissue, thick eschar, or heavy slough will produce disappointing results.

Step 1: Wound Bed Preparation

Sharp debridement is the foundation. Remove all non-viable tissue until punctate bleeding is observed. For plantar DFUs, this often requires aggressive saucerization to eliminate undermining and expose the true wound dimensions. Biofilm disruption through mechanical debridement combined with antiseptic irrigation reduces microbial load below the critical colonization threshold.

Address exudate management before application. Rampart is applied dry and will absorb moderate exudate, but heavily exuding wounds may require a secondary absorbent dressing. For dry wounds, consider hydrating the bed with sterile saline before graft placement.

Step 2: Graft Sizing and Placement

Measure the wound and select a graft size that covers the entire wound bed with a 1-2 mm margin overlap onto periwound skin. The graft should not be stretched or bunched. Gentle contact with the wound surface is the goal.

Remove the graft from its packaging using sterile technique. The dehydrated membrane is fragile when dry but becomes pliable upon hydration with wound exudate or sterile saline. Place the graft with the epithelial side down, contacting the wound bed directly. The stromal side faces upward toward the secondary dressing.

Step 3: Securing the Graft

Secure the graft with a non-adherent contact layer followed by an appropriate secondary dressing based on exudate level. Options include:

• Low exudate: Non-adherent silicone contact layer with a foam or hydrocolloid secondary dressing.
• Moderate exudate: Non-adherent contact layer with an alginate or superabsorbent foam secondary dressing.
• High exudate: Consider an antimicrobial contact layer (silver or PHMB) with a superabsorbent foam or negative pressure wound therapy (NPWT) overlay.

NPWT over amniotic grafts has shown promising results in some studies, with the negative pressure improving graft contact and exudate removal while the biological activity of the membrane accelerates granulation. However, NPWT should be used at lower pressures (75-100 mmHg continuous or 125 mmHg intermittent) to avoid damaging the delicate graft.

Step 4: Offloading and Adjunctive Care

For plantar DFUs, total contact casting (TCC) remains the gold standard for offloading. Removable walker boots are acceptable alternatives if patient compliance is high, but adherence must be verified at each visit. Without effective offloading, even the most biologically active graft will fail.

Continue standard adjunctive care: glycemic control optimization, nutritional assessment and supplementation, smoking cessation support, and vascular assessment with referral for revascularization when indicated.

Step 5: Dressing Changes and Reapplication

The initial dressing should remain in place for 5-7 days to allow graft incorporation. At the first dressing change, assess graft integration. The graft may appear dissolved or incorporated into the wound bed. This is expected and does not indicate failure.

Reapplication frequency depends on wound response. Typical protocols involve weekly application until the wound achieves 50% area reduction, then biweekly application until closure. Some clinicians continue applications until complete epithelialization to support maturation of the new tissue.

Expected Outcomes and Timeline

Clinical evidence for amniotic membrane allografts, including Rampart, supports specific outcome expectations when patient selection and application technique are appropriate.

Time to 50% area reduction: In DFUs, studies consistently show 50% area reduction by week 4-6 with weekly applications, compared to 8-12 weeks with standard care alone. This metric is clinically meaningful because 50% reduction by week 4 is a strong predictor of eventual closure.

Complete wound closure: A 2025 meta-analysis in Wounds found complete closure rates of 68% at 12 weeks for DFUs treated with amniotic membrane allografts, compared to 41% with standard care. For VLUs, closure rates at 12-16 weeks range from 45-60% depending on wound duration and comorbidities.

Healing velocity: Weekly wound area reduction averages 15-25% per week during the active treatment phase, compared to 5-10% with standard care alone.

Infection rates: The antimicrobial peptides present in amniotic membrane (beta-defensins, lactoferrin, lysozyme) contribute to reduced infection rates. Studies report 20-30% reductions in secondary infections compared to standard care.

Reimbursement and Coding

Reimbursement for Rampart Skin Graft varies by payer and setting. Understanding the coding landscape is essential for sustainable practice integration.

Medicare and Commercial Payers

Amniotic membrane allografts are typically billed using HCPCS code Q4122 (Amniotic membrane, dehydrated, per square centimeter) or Q4123 (Amniotic membrane, injectable, per cc), depending on product form and payer requirements. Rampart Skin Graft, as a dehydrated membrane, generally falls under Q4122.

Medicare coverage for skin substitute grafts is governed by local coverage determinations (LCDs) that vary by Medicare Administrative Contractor (MAC). Most LCDs require documentation of:

• Wound duration of at least 4 weeks with documented failure to improve
• Appropriate wound bed preparation (debridement)
• Offloading compliance for plantar wounds
• Regular wound measurements with area calculations
• Progress notes demonstrating response to treatment

Commercial payers may have additional prior authorization requirements. Pre-authorization is strongly recommended before initiating treatment, particularly for plans with high deductibles or limited durable medical equipment coverage.

Documentation Best Practices

Complete documentation protects both patient care and reimbursement. Required elements include:

• Initial wound assessment with measurements (length, width, depth), location, etiology, and duration
• Photographic documentation at baseline and at each visit
• Detailed description of prior treatments and outcomes
• Debridement notes with tissue type removed and wound bed appearance post-debridement
• Graft size applied, lot number, and application date
• Offloading method documented at each visit
• Progress assessment with area reduction calculations

For a deeper dive into reimbursement specifics, see our reimbursement coding guide for amniotic membrane allografts.

Rampart vs Other Amniotic Products

The amniotic membrane market includes multiple products with varying processing methods, preservation techniques, and biological activity profiles. Key differentiators include:

Feature	Rampart Skin Graft	Other Dehydrated Membranes	Cryopreserved Membranes
Storage	Room temperature	Room temperature	Frozen (-80C)
Shelf life	2-3 years	2-3 years	1-2 years
Growth factor retention	Moderate-high	Variable	High
Handling	Easy, no thawing	Easy, no thawing	Requires thawing protocol
Cost per cm2	Mid-range	Variable	Higher

The choice between dehydrated and cryopreserved products depends on clinical setting, storage capacity, handling preferences, and cost considerations. Dehydrated products like Rampart offer convenience and shelf stability that make them practical for outpatient clinics and smaller practices. Cryopreserved products may offer higher growth factor concentrations but require specialized storage and handling.

For a direct product comparison within the dehydrated category, see our AmnioAMP vs Rampart comparison.

Common Application Errors and How to Avoid Them

Even experienced clinicians can compromise outcomes with subtle errors in application or patient management.

Inadequate debridement: The most common error is applying the graft over non-viable tissue. If the wound bed does not bleed when gently scraped, it is not ready. Take the time to debride thoroughly.

Skipping offloading: In DFUs, offloading is as important as the graft itself. A biologically active graft under persistent mechanical stress will fail. Document offloading at every visit and verify compliance.

Incorrect graft orientation: The epithelial side must contact the wound bed. While most products are packaged with orientation indicators, double-check before application. Reversing the graft places the stromal matrix against the wound, reducing growth factor delivery.

Over-tight dressings: Dressings that compress the graft excessively can compromise blood flow to the wound bed. Secure the graft firmly but not tightly. The goal is contact, not compression.

Premature discontinuation: Some clinicians stop applications at first signs of improvement. Wounds that stall at 70-80% closure often benefit from continued applications until complete epithelialization. Set clear criteria for discontinuation based on wound trajectory, not calendar dates.

Integration Into Practice Workflow

Successful integration of Rampart Skin Graft into clinical practice requires workflow adjustments, not just product knowledge.

Inventory management: Maintain a stock of common graft sizes (2x2 cm, 4x4 cm, 6x6 cm, and sheets) to avoid treatment delays. Dehydrated products have long shelf lives, so stock rotation is minimal.

Staff training: All clinical staff involved in wound care should understand indications, contraindications, application technique, and documentation requirements. Consider competency validation for new staff.

Patient education: Patients should understand why they are receiving an advanced biologic, what to expect during treatment, and their role in offloading and wound protection. Written materials improve compliance.

Outcome tracking: Implement a system for tracking wound area reduction, time to closure, and infection rates. This data supports quality improvement, payer negotiations, and clinical decision-making.

The Bottom Line

Rampart Skin Graft represents a practical, evidence-based option for clinicians managing chronic wounds that have stalled despite standard care. Its biological activity, ease of handling, and room-temperature storage make it suitable for a wide range of clinical settings.

The key to success is not the graft itself but the system around it: proper patient selection, thorough wound bed preparation, effective offloading, consistent application, and meticulous documentation. Amniotic membrane allografts are powerful tools, but they are tools. They require skilled operators and appropriate clinical infrastructure to deliver their full potential.

For clinicians ready to integrate advanced biologics into their wound care practice, Rampart Skin Graft offers a balance of clinical efficacy, practical handling, and reimbursement viability that makes it a strong candidate for formulary inclusion.